HF
PRLD icon

HRT Financial’s Prelude Therapeutics PRLD Stock Holding History

HRT Financial’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Buy
+58,699
New +$154K ﹤0.01% 3199
2025
Q4 		– Sell
-16,901
Closed -$24K – 3849
2025
Q3 		$24K Buy
+16,901
New +$16.9K ﹤0.01% 2685
2023
Q2 		– Sell
-22,175
Closed -$126K – 3100
2023
Q1 		$126K Buy
+22,175
New +$135K ﹤0.01% 2021
2022
Q1 		– Sell
-114,249
Closed -$1.42M – 3700
2021
Q4 		$1.42M Buy
114,249
+98,690
+634% +$1.61M 0.01% 873
2021
Q3 		$486K Buy
+15,559
New +$504K ﹤0.01% 2022

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HRT Financial's PRLD Position: Q1 2026 in Review

HRT Financial opened a new position in Prelude Therapeutics (PRLD) in Q1 2026: 58,699 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #3199 among its holdings. This is a return to the name: HRT Financial previously reported a position in PRLD as recently as Q3 2025.

HRT Financial first reported a position in PRLD in Q3 2021 and has held it in 5 quarters since. The position peaked at $1.42M in Q4 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • HRT Financial held 58,699 shares of Prelude Therapeutics worth $200K as of Q1 2026.
  • Prelude Therapeutics was a new HRT Financial position in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3199 holding.
  • HRT Financial first reported a position in Prelude Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • HRT Financial's Prelude Therapeutics position peaked at $1.42M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.